Seegene Records 113.5 Billion Won In Q3 Revenue...Operating profit increased 82.8% year-on-year
Nov 07, 2025
|
According to the disclosure on the 7th, Seegene's sales and operating profit increased by 4.3% and 82.8% year-on-year, continuing a clear improvement in performance. In particular, operating profit increased 197.9% compared to 3.1 billion won in the previous year, maintaining a clear surplus from the first half of this year.
Reagent sales combined with diagnostic reagents and extraction reagents, which are Seegene's main products, accounted for 77.2% of total sales, reaching 87.7 billion won. In particular, sales of Virocona products among diagnostic reagents reached 74.4 billion won, or 84.9% of total reagent sales, sales of extraction reagents reached 10.9 billion won and sales of Corona products recorded 2.4 billion won.
Of these, sales of diagnostic reagents were driven by the non-respiratory syndrome family offsetting seasonal variability in respiratory products.
Sales of all non-respiratory products grew 18.0% year-on-year, with fire extinguisher (GI) products up 11.7% to 21.5 billion won, human papillomavirus (HPV) products up 30.2% to 10.8 billion won, and sexually transmitted infectious disease (STI) products up 8.8% to 16.5 billion won.
Kim Jeong-yong, head of Seegene's financial management office, said "The overall cost efficiency was achieved, including the reduction of costs such as SG&A expenses and the increase in financial income due to fluctuations in the euro exchange rate."We expect sales and profitability to improve further, especially in the fourth quarter, with the recovery of the respiratory product line due to global seasonal factors."
Reporter Kim So-hyung compact@sportschosun.com
This article was translated by Naver AI translator.
